

If your loved one has PSMA+ mCRPC previously treated  
with hormone therapy and chemotherapy,

CONSIDER

# PLUVICTO

A GUIDE FOR  
CARE PARTNERS:  
Tips for advocates

Actor portrayal.

## What is PLUVICTO<sup>®</sup> (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

- has spread to other parts of the body (metastatic), and
- has already been treated with other anticancer treatments

## IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.

Please see additional [Important Safety Information](#) on pages 10-12.

# As a care partner YOUR SUPPORT MATTERS

You've heard your loved one's cancer is metastatic. Now your involvement can be crucial to help him. It can make a difference. The steps below can help you advocate for him:



## **Start the conversation. Ask your loved one and his doctor questions:**

- What does it mean to have mCRPC?  
How does that affect treatment options?
- What past tests and treatments has my loved one had?  
Are there any to discuss?
- What are our goals for treatment?

mCRPC, metastatic castration-resistant prostate cancer.


## **IMPORTANT SAFETY INFORMATION (continued)**

### **What is the most important information I should know about PLUVICTO? (continued)**

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional [Important Safety Information](#) on [pages 10-12](#).

# YOUR SUPPORT MATTERS (continued)



## Find a path forward on your journey

Some treatments may better fit your loved one's and his doctor's treatment goals. Your advocacy can help in finding the best options for him.



## Your loved one's treatment options

Doing your own research can help. There are many information resources, including [PLUVICTO.com](http://PLUVICTO.com).

Talk to the care team about all treatment options and ask if PLUVICTO may be right for your loved one.

## IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

- **Low level of blood cell counts.** Tell your doctor right away if you develop any new or worsening symptoms, including:
  - Tiredness or weakness

Please see additional [Important Safety Information](#) on [pages 10-12](#).



*"I would not be who I am today  
and where I am without support.  
It's that important."*

- A patient with mCRPC, about his care partner

#### IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding

Actor portrayal.

Please see additional [Important Safety Information](#) on pages 10-12.

# A DIFFERENT TREATMENT

After all you and your loved one have been through, you know that **every option matters**

If your loved one has had:

**1** + **1** = **Ask about PLUVICTO,**  
hormone therapy (pills)      chemotherapy      a different treatment that could change his journey

Find out his PSMA status  
by asking for a PSMA-PET scan, to see  
if PLUVICTO could be right for him.

**Hormone therapy:** Treatment that interferes with the effects of testosterone.

**Chemotherapy:** Treatment that uses chemicals to kill fast-growing cells in the body. This includes cancer cells.

PET, positron emission tomography; PSMA, prostate-specific membrane antigen.

## IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers
- **Kidney problems.** Tell your doctor right away if you develop any new or worsening symptoms, including passing urine less often or passing much smaller amounts of urine than usual

Please see additional [Important Safety Information](#) on pages 10-12.

# WHAT IS PSMA?

PSMA (prostate-specific membrane antigen) is a biomarker that can be found on prostate cancer cells and some normal cells. If your loved one has higher levels of PSMA, he is considered PSMA+.

Your loved one can find out if he is PSMA+ by having an imaging test called a PSMA-PET scan.

>80%

of men with prostate cancer are PSMA+.  
This means your loved one may be too.

**Biomarker:** Something that can tell the doctor more about your loved one's cancer.

**PSMA-PET scan:** An imaging test that can find PSMA+ cells, including prostate cancer cells, in the body.

PSMA+, PSMA positive.

## IMPORTANT SAFETY INFORMATION (continued)

Before you receive PLUVICTO, tell your doctor if any of these apply to you:

- You have low level of blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)
- You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (possible signs of myelosuppression)
- You have or have had kidney problems
- You have or have had any other type of cancer or treatment for cancer, as PLUVICTO contributes to your long-term cumulative radiation exposure

Please see additional [Important Safety Information](#) on pages 10-12.

# WHAT IS PLUVICTO?

PLUVICTO is not chemotherapy. It is the **FIRST** and **ONLY** radioligand therapy (RLT) for PSMA+ mCRPC

- RLT is a different type of radiation therapy that is injected and targets the biomarker PSMA
- This means it is designed to find and attack PSMA+ cells, including cancer cells\*

\*May also damage healthy PSMA+ and other nearby cells.

## IMPORTANT SAFETY INFORMATION (continued)

Before you receive PLUVICTO, tell your doctor if any of these apply to you (continued):

- You are sexually active as:
  - All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby
  - You should use effective contraception for intercourse during treatment with PLUVICTO and for 14 weeks after your last dose
  - PLUVICTO may cause temporary or permanent infertility

Before administration of PLUVICTO, you should drink plenty of water in order to urinate as often as possible during the first hours after administration.

Please see additional [Important Safety Information](#) on [pages 10-12](#).

# WHY PLUVICTO?

A chance for more time with him. That's a **VICTORY**.

The VISION trial included 831 men with PSMA+ prostate cancer that spread outside their prostate. They were divided into two groups:

- 551 men were treated with PLUVICTO plus standard therapy\*
  - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 280 men were treated with standard therapy alone

In VISION, PLUVICTO was shown to:

**15** months **Help patients live longer**  
Median overall survival (OS) was about **15 months** for men on PLUVICTO plus standard therapy compared to about **11 months** on standard therapy alone.

**9** months **Give people more time without cancer worsening**  
Median radiographic progression-free survival (rPFS) was about **9 months** for men on PLUVICTO plus standard therapy compared to about **3.5 months** with standard therapy alone.†

**30%** of men **Help tumors shrink or disappear**  
On PLUVICTO plus standard therapy, **30%** of men saw their tumors shrink or disappear compared to **2%** with standard therapy alone.

This data point is called overall response rate (ORR), which is calculated by adding complete response (CR) and partial response (PR), which was:

- CR: **6%** with PLUVICTO vs **0%** with standard therapy
- PR: **24%** with PLUVICTO vs **2%** with standard therapy

\*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (<sup>223</sup>Ra), or drugs still being studied.

†rPFS results may be misread. In the clinical trial, many patients treated with standard therapy alone dropped out early.

The most common side effects of PLUVICTO include:

- Tiredness
- Dry mouth
- Nausea
- Low red blood cell count
- Loss of appetite
- Changes in bowel movements (constipation or diarrhea)
- Vomiting
- Low blood platelet count
- Urinary tract infection
- Weight loss
- Abdominal pain

Please see additional [Important Safety Information](#) on pages 10-12.





*"Trust your gut  
and advocate for the patient.  
I wanted to get things accomplished that would help."*

*- Care partner of a man with PSMA+ mCRPC*

## IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Tiredness
- Dry mouth
- Nausea
- Low red blood cell count
- Loss of appetite
- Changes in bowel movements (constipation or diarrhea)
- Vomiting
- Low blood platelet count
- Urinary tract infection
- Weight loss
- Abdominal pain

Actor portrayal.

Please see additional [Important Safety Information](#) on pages 10-12.

## IMPORTANT SAFETY INFORMATION

### What is PLUVICTO<sup>®</sup> (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

- has spread to other parts of the body (metastatic), and
- has already been treated with other anticancer treatments

## IMPORTANT SAFETY INFORMATION

### What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

### PLUVICTO may cause serious side effects, including:

- **Low level of blood cell counts.** Tell your doctor right away if you develop any new or worsening symptoms, including:
  - Tiredness or weakness
  - Pale skin
  - Shortness of breath
  - Bleeding or bruising more easily than normal or difficulty stopping bleeding
  - Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers
- **Kidney problems.** Tell your doctor right away if you develop any new or worsening symptoms, including passing urine less often or passing much smaller amounts of urine than usual

Please see full [Prescribing Information here](#).

## IMPORTANT SAFETY INFORMATION (continued)

Before you receive PLUVICTO, tell your doctor if any of these apply to you:

- You have low level of blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)
- You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (possible signs of myelosuppression)
- You have or have had kidney problems
- You have or have had any other type of cancer or treatment for cancer, as PLUVICTO contributes to your long-term cumulative radiation exposure
- You are sexually active as:
  - All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby
  - You should use effective contraception for intercourse during treatment with PLUVICTO and for 14 weeks after your last dose
  - PLUVICTO may cause temporary or permanent infertility

Before administration of PLUVICTO, you should drink plenty of water in order to urinate as often as possible during the first hours after administration.

The most common side effects of PLUVICTO include:

- Tiredness
- Dry mouth
- Nausea
- Low red blood cell count
- Loss of appetite
- Changes in bowel movements (constipation or diarrhea)
- Vomiting
- Low blood platelet count
- Urinary tract infection
- Weight loss
- Abdominal pain

Please see full [Prescribing Information here](#).

## IMPORTANT SAFETY INFORMATION (continued)

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please see full [Prescribing Information here](#).



Speak with  
your loved one  
and his doctor  
about PLUVICTO.

Actor portrayal.

Download the doctor discussion guide to start the conversation.

Ask his doctor about a PSMA-PET scan and PLUVICTO.  
USE **THIS GUIDE** TO PREPARE.

## IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.



Novartis Pharmaceuticals Corporation  
East Hanover, New Jersey 07936-1080

© 2024 Novartis



11/24

FA-11295758

Please see additional Important Safety Information on pages 10-12.